Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Afya Limited AFYA

Consumer Defensive — Education & Training Services
Cash Flow Champion (5y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
3.20
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — 3 7 — 2 1 — —
Insider Ownership
90.61%

Capital & Financial Ratios

Market Cap
1,250.00
Revenue
724.76
Net Income
170.65
Free Cash Flow
242.31
Net Debt
206.09
Current Ratio
2.20
Debt/Equity
0.42
P/E ratio
8.24
P/S ratio
1.67
P/B ratio
1.24
Past 5Y EPS Growth
20.41%
This Y EPS Growth
(7.05%)
Next Y EPS Growth
11.35%
Next 5Y EPS Growth
3.41%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
0.13%
total individual payouts
2028 ‡‡‡‡‡
2027 ‡‡‡‡‡
2026 0.66
—
2025 0.27
—
2024 ‡‡‡‡‡
2023 ‡‡‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡‡‡
2019 ‡‡‡‡‡
2018 ‡‡‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 110.77 168.90 201.56 199.18
Receivables 118.21 115.25 135.01 173.79
Inventory 0.28 — — —
Other 11.80 10.59 11.27 12.96
241.06 294.75 347.84 385.94
2023 2024 2025 Q'26
Payables 92.58 58.10 41.95 39.93
ST’ Debt 35.90 67.40 10.87 25.01
Other 31.30 31.87 29.91 22.25
212.03 211.39 158.33 175.31
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡‡‡ ‡‡‡‡‡
Earnings — ‡‡‡‡‡ ‡‡‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 192.31 192.38 — —
—
’25 159.84 162.27 170.47 169.59
662.18
’24 162.38 155.17 151.67 143.41
612.62
’23 136.67 143.95 148.17 147.26
576.05
’22 108.39 121.55 110.77 110.42
451.14
’21 72.17 70.30 86.97 89.16
318.60
’20 61.51 51.14 57.58 62.80
233.03
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 88.64 69.25 — —
—
’25 79.18 57.01 98.41 39.71
274.31
’24 84.37 43.46 79.19 58.60
265.62
’23 63.82 44.75 74.97 25.50
209.04
’22 53.35 33.61 49.64 26.87
163.46
’21 32.81 27.71 40.68 15.71
116.90
’20 22.91 12.42 22.16 14.58
72.07
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 80.14 54.01 — —
—
’25 67.10 33.85 85.33 22.83
209.11
’24 60.62 36.15 43.05 38.37
178.19
’23 54.89 33.05 63.83 (6.22)
145.55
’22 43.33 20.76 36.81 5.03
105.93
’21 26.78 18.45 29.03 (8.65)
65.61
’20 18.20 8.67 16.92 1.59
45.38
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.54 0.44 — —
—
’25 0.47 0.33 0.31 0.35
1.49
’24 0.45 0.33 0.24 0.28
1.29
’23 0.24 0.19 0.21 0.22
0.86
’22 0.27 0.23 0.16 0.14
0.80
’21 0.21 0.03 0.11 0.09
0.44
’20 0.25 0.12 0.15 0.12
0.61

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

3.5
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.73 9.66 14.52 13.47 — — —
Low Price
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.02 22.41 22.48 19.90 — — —
High Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8,708 9,680 9,717 9,395 — — —
Employees
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.05 0.06 0.06 0.07 — — —
Revenue/Emp
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 451.14 576.05 612.62 662.18 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 63.09% 61.41% 63.21% 64.46% — — —
Gross Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 82.99 86.05 125.40 154.20 ‡‡‡‡‡ — —
EBT
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18.40% 14.94% 20.47% 23.29% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 82.99 86.05 125.40 154.20 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39.94 57.99 61.80 66.87 — — —
Depreciation
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.99 6.41 6.80 7.32 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 0.80 0.86 1.30 1.49 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.81 2.33 2.95 3.03 ‡‡‡ — —
Cash Flow/Sh
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.64) (0.71) (0.97) (0.72) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.17 1.62 1.98 2.31 — — —
Free CF/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.97 8.12 8.87 9.68 ‡‡‡‡‡ — —
Book Value/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 90.34 89.83 90.12 90.48 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.24 24.76 12.03 10.41 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.24 3.32 2.34 2.11 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.32 2.62 1.79 1.59 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.58 3.75 2.72 2.36 ‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 15.25 14.86 9.37 7.46 — — —
EV/FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 163.46 209.04 265.62 274.31 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (57.53) (63.48) (87.42) (65.19) ‡‡‡‡‡ — —
Capex
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 105.93 145.55 178.19 209.11 ‡‡‡‡‡ — —
FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 141.78 29.03 83.35 189.51 — — —
Working Cap'
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 364.72 360.70 406.98 367.92 — — —
Total Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 152.99 249.92 238.08 166.36 — — —
Net Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 629.56 729.70 799.18 876.01 — — —
Sh' Equity
— ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.59% 5.31% 7.42% 8.14% ‡‡‡‡‡ — —
ROA
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.27% 9.80% 11.31% 13.03% — — —
ROIC
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.21% 11.39% 15.32% 16.09% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Afya Limited (AFYA), a key player in Brazil’s burgeoning medical education sector, has shown impressive resilience amid emerging market turbulence, with revenue exploding from $91 million in 2018 to a projected $715 million in 2025—a 686% surge driven by organic enrollment growth, strategic acquisitions, and demographic tailwinds like an aging population and healthcare shortages. Gross margins have held steady at 61-63%, free cash flow per share has more than tripled to $1.98, and profitability metrics like ROE have climbed to 15.3%, outpacing peers, underscoring scalable operations in a regulated market.

The balance sheet remains a strong pillar, with equity up 49% to $799 million and net debt stabilizing at $238 million against robust operating cash flows, though rising debt warrants monitoring amid Brazil’s FX volatility and inflation risks. Valuation metrics scream undervaluation—trailing P/E at 12x, EV/Sales at 2.7x versus historical highs and peers—decoupling from fundamentals as the stock trades 85-90% below peaks despite tripled revenue and FCF.

Analyst targets suggest 490-750% upside potential through 2027 on 15-20% EPS CAGR, fueled by capacity expansions and digital shifts, but regulatory caps, macroeconomic headwinds, and EM sentiment could temper gains. For conservative investors eyeing steady compounders, Afya’s moat in Brazil’s $10B+ med-ed space merits a closer look at the full analysis.

Read full commentary →

Afya Limited (AFYA) Latest News

News by impact score

Fine-tune

18 Sep

3 , 9:22 AM
Afya Limited announces increase in medical seats at AFYA Cruzeiro do Sul. Medical seat increase at one unit supports enrollment growth and revenue but remains localized.

24 Aug

4 , 9:26 AM
Afya Limited issued comments on Yduqs Participações S.A.'s disclosure of a potential business combination. Potential business combination represents a major strategic development that could reshape Afya's operations and market trajectory.

20 Aug

4 transcript www.fool.com, 7:39 PM
Afya Limited held its Q2 2026 earnings call, covering financial results, operational metrics, and forward outlook for the medical education company. Quarterly earnings calls deliver key results and guidance that directly shape near-term valuation and investor positioning.

14 Aug

3 , 9:10 PM
Afya Ltd reported solid growth in Q2 2026 alongside strategic capital returns. Earnings growth and capital returns point to noticeable but not transformative effects on Afya Limited performance.

3 transcript app.moby.co, 8:30 AM
Afya Limited conducted its Q2 2026 earnings call, covering financial results, operational metrics, and forward guidance. Quarterly earnings and guidance directly shape near-term investor views and valuation multiples.

13 Aug

3 transcript www.marketbeat.com, 8:03 PM
Afya Limited conducted its Q2 earnings call, covering quarterly financial results, operational metrics, and forward guidance for the education services provider. Q2 earnings details and guidance offer moderate insight into near-term financial trajectory without indicating major strategic shifts.

3 , 6:06 PM
Afya Limited released financial results for the second quarter and first half of 2026. Quarterly earnings releases deliver performance data that can shift near-term investor sentiment and valuation.

8 May

4 GuruFocus.com, 9:00 PM
Afya Ltd (AFYA) reported strong revenue growth in Q1 2026 earnings call highlights, navigating competitive pressures effectively. Strong Q1 2026 revenue growth despite competition significantly boosts Afya's financial performance and investor sentiment.

7 May

4 Business Wire, 8:42 PM
Afya Limited announced its first-quarter 2026 financial results. Quarterly earnings announcements directly affect financial performance, investor sentiment, and stock trajectory.

3 www.marketbeat.com, 7:42 PM
Afya Limited's Q1 earnings call highlighted robust revenue growth, EBITDA margins expansion, student enrollment increases, and reaffirmed full-year guidance amid strong operational performance. Q1 results show moderate financial improvements influencing near-term performance and sentiment without transformative changes.

5 May

3 Business Wire, 8:59 PM
Moody's reaffirmed Afya Limited's AAA.br national scale rating with a stable outlook, citing the company's robust financial profile, market leadership in Brazilian higher education, and solid liquidity. Reaffirmation of top-tier AAA.br rating with stable outlook bolsters financial credibility and supports sustained market performance amid economic uncertainties.

24 Mar

3 Simply Wall St., 8:05 AM
Analysts are turning more cautious on Afya Limited (AFYA), shifting the company's investment story amid concerns over its outlook. Increased analyst caution signals moderately noticeable downward pressure on AFYA's investor sentiment and stock performance.

20 Mar

4 Zacks, 12:20 PM
Surging earnings estimates signal upside potential for Afya Limited (AFYA) stock. Surging earnings estimates indicate improved financial outlook, likely boosting investor sentiment and stock performance.

13 Mar

4 GuruFocus.com, 9:02 PM
Afya Ltd (AFYA) reported strong revenue growth and announced strategic investments during its Q4 2025 earnings call. Strong revenue growth combined with strategic investments positions Afya Ltd for significant enhancements in future performance and market standing.

12 Mar

4 Zacks, 10:45 PM
Afya Limited (AFYA) beat Q4 earnings estimates, delivering stronger-than-expected financial results. Beating Q4 earnings estimates demonstrates robust financial performance, likely driving positive investor sentiment and upward stock momentum.

4 Associated Press Finance, 9:39 PM
Afya Limited (AFYA) released its Q4 earnings snapshot. Q4 earnings snapshots reveal financial performance that significantly influences stock price and investor sentiment.

4 Business Wire, 8:21 PM
Afya Limited announced fourth quarter and twelve months 2025 financial results. Quarterly and annual earnings announcements significantly influence Afya Limited's financial performance outlook and stock trajectory.

4 www.marketbeat.com, 7:46 PM
Afya Limited released Q4 earnings call highlights covering financial results, operational updates, and future outlook. Q4 earnings call highlights deliver key financial metrics and guidance that significantly shape Afya Limited's market performance and investor expectations.

3 Business Wire, 5:10 PM
Afya Limited announces dividend distribution of R$307.4 million. Substantial dividend payout signals strong cash flow and shareholder focus, moderately enhancing financial perception and market sentiment.

26 Feb

4 Insider Monkey, 9:54 PM
Bank of America turns pessimistic on Afya Limited (AFYA). BofA's downgrade signals major shift in investor sentiment and potential stock price decline.

6 Feb

4 Business Wire, 8:38 AM
Afya Limited has announced an increase in medical school seats at its Afya Abaetetuba campus, aiming to enhance healthcare education and address the growing demand for medical professionals in Brazil. This expansion is part of Afya's strategy to strengthen its educational offerings and improve access to medical training in the region. Increasing medical seats is a significant strategic move that could enhance Afya's competitive positioning and market presence.

2 Feb

4 Simply Wall St., 6:26 AM
Afya Limited (NASDAQ: AFYA) is implementing strategic initiatives aimed at enhancing its market position and driving share price growth. The company is focusing on expanding its services and improving operational efficiencies, which are expected to yield positive financial results. Analysts are optimistic about Afya's potential to capitalize on market opportunities and strengthen its competitive edge in the healthcare sector. Strategic initiatives and market expansion efforts are likely to significantly impact Afya's future performance and investor sentiment.

31 Jan

3 Insider Monkey, 7:59 AM
UBS has expressed concerns regarding Afya Limited's near-term outlook, attributing potential challenges to increased spending. The financial services firm anticipates that higher costs may impact the company's performance in the upcoming quarters, leading to a cautious stance on its growth prospects. Investors are advised to monitor these developments closely as they could influence market sentiment towards Afya Limited. Increased spending is expected to moderately affect Afya Limited's financial performance and market positioning.

15 Jan

3 ZacksZacksZacksZacksZacksZacksZacksZacks, 8:30 AM
Options trading activity for Afya Limited (AFYA) has surged, with a notable increase in call options, suggesting that traders may anticipate a significant price movement. The heightened interest in options could indicate expectations of upcoming news or events that could impact the stock's performance. Analysts are observing this trend closely, as it may reflect broader market sentiment or insider knowledge regarding the company's future prospects. Increased options trading activity may indicate market expectations that could moderately influence Afya's stock performance.

10 Jan

4 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 8:21 AM
Afya Limited (NASDAQ:AFYA) has shown promising financial prospects, with recent performance indicating potential growth driven by strategic initiatives and market demand. The company's focus on expanding its services and improving operational efficiency is expected to enhance its competitive positioning. Analysts are optimistic about Afya's ability to capitalize on emerging opportunities in the healthcare sector, which could lead to sustained revenue growth and profitability. However, market conditions and regulatory factors may influence the overall trajectory. Significant strategic initiatives and market demand are likely to impact Afya's future performance.

21 Dec

3 Simply Wall St., 9:27 AM
Afya Limited (NASDAQ: AFYA) shareholders have experienced a decline in their investments over the past five years, with the stock price falling significantly. The company's performance has been affected by various market conditions and operational challenges, leading to a negative return for long-term investors. Despite these setbacks, analysts suggest that the company may have potential for recovery in the future, depending on strategic decisions and market dynamics. The decline in stock price indicates a moderately noticeable influence on investor sentiment and financial performance.

17 Dec

3 Business Wire, 5:22 PM
Afya Limited has announced changes to its Board of Directors, which include the appointment of new members and the resignation of others. These changes are part of the company's strategy to enhance governance and align with its growth objectives. The new board members bring diverse expertise that is expected to contribute positively to Afya's future direction. Board changes may moderately influence the company's strategic direction and governance.

4 Dec

4 Insider Monkey, 8:34 AM
Afya Limited (AFYA) is positioned for growth due to its strategic initiatives in the healthcare sector, focusing on expanding its digital health services and enhancing educational offerings. The company aims to leverage technology to improve patient outcomes and streamline operations, which could lead to increased market share and revenue. Analysts are optimistic about AFYA's potential to capitalize on the growing demand for healthcare solutions in Brazil, suggesting that its innovative approach may attract more investors and boost its stock performance in the long term. Strategic initiatives and market demand for healthcare solutions are likely to significantly impact Afya's future performance.

24 Nov

3 Simply Wall St., 2:07 AM
Afya Limited's stock performance is under scrutiny as price momentum slows, raising questions about whether shares are undervalued. Analysts are assessing the company's financial health and market position amidst changing dynamics in the healthcare sector. Investors are encouraged to consider the potential for growth and the implications of current market trends on Afya's future. Current market trends and price momentum could moderately influence Afya's financial performance and investor sentiment.

19 Nov

4 transcript GuruFocus.com, 8:02 PM
Afya Limited (AFYA) reported strong revenue growth in its Q3 2025 earnings call, highlighting strategic expansion initiatives that are expected to enhance its market position. The company emphasized its commitment to innovation and improving healthcare services, which contributed to positive financial results. Management outlined plans for future growth and investment in technology to further strengthen its competitive edge. Significant strategic expansion and revenue growth are likely to alter the company's trajectory and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us